Oct 13 (Reuters) - The U.S. government has awarded diagnostic testing company Cue Health Inc $481 million to scale up the production of rapid COVID-19 molecular test, the Department of Health and ...
Home diagnostics company Cue Health announced its received FDA de novo authorization for its at-home COVID-19 test, dubbed the Cue COVID-19 Molecular Test. The Cue COVID-19 Molecular Test detects ...
The FDA granted emergency use authorization June 12 to healthcare tech company Cue Heath’s rapid COVID-19 test. The single-use molecular test identifies the RNA of the virus that causes COVID-19 from ...
As folks travel to see loved ones for the holiday season, there’s one thing no one wants to pack — an infectious disease. But whether you have the sniffles or just want to take precautions around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results